Author

Hans C Rümke

Observed names: H C RUMKE, H C Rumke, H C Rümke, H RUMKE, H Rumke, H Rümke, H. C Rumke, H. C. Rumke, H. C. Rümke, H. Rümke, H.C Rümke, H.C. Rumke, H.C. Rümke, H. C. Rumke, Hans C. Rumke, Hans C. Rümke, Hans Rümke, Hans. C. Rümke, Hans C Rümke, RUMKE, H

Observed institutions: University of Copenhagen, Utrecht University, Leiden University Medical Center, Hvidovre Hospital, Erasmus MC, Amsterdam UMC Location University of Amsterdam, University Medical Center Utrecht, GlaxoSmithKline (Belgium), National Institute for Public Health and the Environment, Netherlands Maritime Technology, Helios Park-Klinikum Leipzig, Zaans Medisch Centrum, Netherlands Pharmacovigilance Centre Lareb, Erasmus MC - Sophia Children’s Hospital, University of Amsterdam, Erasmus University Rotterdam

OpenAlex ID: A5069630359

Immunization of Early Adolescent Females with Human Papillomavirus Type 16 and 18 L1 Virus-Like Particle Vaccine Containing AS04 Adjuvant

2007 · Court Pedersen, Tiina Petaja, et al. · Journal of Adolescent Health · 241

Reemergence of Pertussis in the Highly Vaccinated Population of The Netherlands: Observations on Surveillance Data

2000 · Hester E. de Melker, J.F.P. Schellekens, et al. · Emerging infectious diseases · 227

Pneumococcal vaccines: an update on current strategies

2003 · D Bogaert, P.W.M Hermans, et al. · Vaccine · 189

Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins

1999 · Keith Cartwright, Rhonwen Morris, et al. · Vaccine · 176

Pertussis in the Netherlands: an Outbreak Despite High Levels of Immunization with Whole-Cell Vaccine

1997 · H.E. de Melker, M.A.E. Conyn-van Spaendonck, et al. · Emerging infectious diseases · 157

Phase I clinical trial with a hexavalent PorA containing meningococcal outer membrane vesicle vaccine

1996 · C.C.A.M. Peeters, H.C. Rümke, et al. · Vaccine · 155

Varicella vaccination in Europe – taking the practical approach

2009 · Paolo Bonanni, Judith Breuer, et al. · BMC Medicine · 153

Vaccine-induced antibody responses as parameters of the influence of endogenous and environmental factors.

2001 · H Van Loveren, J G Van Amsterdam, et al. · Environmental Health Perspectives · 141

The epidemiology of varicella and herpes zoster in The Netherlands: Implications for varicella zoster virus vaccination

2006 · Hester de Melker, Guy Berbers, et al. · Vaccine · 138

Comparative immunogenicity of a PreS/S hepatitis B vaccine in non- and low responders to conventional vaccine

2006 · Pamela Rendi-Wagner, Daniel Shouval, et al. · Vaccine · 137

Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children of 2–3 and 7–8 years of age

2000 · Ester D de Kleijn, Ronald de Groot, et al. · Vaccine · 137

A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged ≥65 years

2011 · T.F. Schwarz, J. Flamaing, et al. · Vaccine · 94

Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial

2008 · Hans C. Rümke, José-María Bayas, et al. · Vaccine · 92

No epidemiological evidence for infant vaccinations to cause allergic disease

2004 · S Koppen, R de Groot, et al. · Vaccine · 86

The nuclear symptom of schizophrenia and the praecoxfeeling

1990 · H.C. Rumke, J. Neeleman · History of Psychiatry · 85

Serum bactericidal activity and isotype distribution of antibodies in toddlers and schoolchildren after vaccination with RIVM hexavalent PorA vesicle vaccine

2001 · Ester de Kleijn, Lilian van Eijndhoven, et al. · Vaccine · 50

Rate of recurrent collapse after vaccination with whole cell pertussis vaccine: follow up study

1998 · P. E Vermeer-de Bondt, J. Labadie, et al. · BMJ · 49

Specific Interferon γ Detection for the Diagnosis of Previous Q Fever

2013 · Teske Schoffelen, Leo A. B. Joosten, et al. · Clinical Infectious Diseases · 46

Economic evaluation of meningococcal serogroup C conjugate vaccination programmes in The Netherlands and its impact on decision-making

2004 · R WELTE, G DOBBELSTEEN, et al. · Vaccine · 45

Improved body weight and performance status and reduced serum PGE2 levels after nutritional intervention with a specific medical food in newly diagnosed patients with esophageal cancer or adenocarcinoma of the gastro‐esophageal junction

2015 · Joyce Faber, Madeleen J. Uitdehaag, et al. · Journal of Cachexia Sarcopenia and Muscle · 43

Impact and cost-effectiveness of different vaccination strategies to reduce the burden of pneumococcal disease among elderly in the Netherlands

2018 · Dominic Thorrington, Leo van Rossum, et al. · PLoS ONE · 42

Poliomyelitis in the Netherlands: a review of population immunity and exposure between the epidemics in 1978 and 1992

1995 · H. C. Rümke, P. M. Oostvogel, et al. · Epidemiology and Infection · 38

Implementation of a Q fever vaccination program for high-risk patients in the Netherlands

2013 · Leslie D. Isken, Marleen Kraaij-Dirkzwager, et al. · Vaccine · 37

Selection of an adjuvant for seasonal influenza vaccine in elderly people: modelling immunogenicity from a randomized trial

2013 · Hans C Rümke, Jan Hendrik Richardus, et al. · BMC Infectious Diseases · 34

Immunogenicity and safety of a live attenuated shingles (herpes zoster) vaccine (Zostavax®) in individuals aged ≥ 70 years: A randomized study of a single dose vs. two different two-dose schedules

2013 · Timo Vesikari, Roland Hardt, et al. · Human Vaccines & Immunotherapeutics · 33

Works count: 84

Citation count: 3,067

H-index: 29

I10-index: 44